$5.600
-0.165 (-2.95%)Zum Schluss
SISI-News
SISI-Events
Shineco Secures $8.7 Million Technology Services Agreement and Reveals Partnership with BICC
Shineco subsidiary, Xi'an Dong'ao Health Management has signed a technology services contract valued at $8.7M with Xinke Future Biotechnology for the research and development of "microalgae-derived extracellular vesicles" technology. Separately, a delegation from Singapore's biotechnology company, BICC, completed a productive site visit to Dong'ao Health on September 10. The parties reached a broad consensus on key collaboration areas, including establishing a joint laboratory and a technology exchange mechanism, marking a substantive step forward in Shineco's "technology industrialization and global synergy" strategy in the biocellular field. As the core entity executing Shineco's strategy in the biocellular market, Dong'ao Health's new contract focuses on cutting-edge microalgae-derived extracellular vesicles technology. The service period runs from August 25, 2025, to December 31, 2026, with the goal of building a comprehensive, end-to-end R&D system from basic research to process development and product translation. Specific tasks include functional validation during the basic research phase; breaking bottlenecks in large-scale separation and extraction processes to achieve mass production; and developing at least two therapeutic products with full regulatory support to effectively transition the technology from the lab to the market. The total value of $8.7M will be paid in phases, with an initial payment of $560,000 already received. Subsequent payments are tied to R&D milestones, ensuring stable revenue recognition and creating long-term profit growth drivers through the "develop once, deploy multiple times" nature of the technology. Concurrent with this R&D progress, Shineco's international cooperation achieved a key milestone. BICC sent a high-level delegation to Dong'ao Health from September 6-10, including Chairman Yang Shengnan, CEO Barbara Tan, CFO Jon Lim, Chief Scientist Chen Yanming, and shareholder Chen Laifu. The delegation conducted on-site inspections of Dong'ao Health's four core segments-the Health and Wellness Center, Cell R&D Center, under-construction Alzheimer's Disease Care Town, and partner "Anhe Meige Medical Aesthetic Hospital"-to evaluate potential synergies. The parties agreed to establish a joint laboratory, implement a technology exchange mechanism, integrate BICC's network of over 3,000 agents in Southeast Asia with Dong'ao Health's domestic wellness channels, and co-establish stem cell transfusion centers to promote standardized clinical services.
Shineco subsidiary reaches large-scale production of high-purity soybean phospholipids
Shineco announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale production of high-purity, highly active free-form soybean phospholipids. This breakthrough was made possible through its proprietary APCC-UF pure physical extraction technology, overcoming a persistent global technical challenge in the field. Testing by multiple authoritative institutions confirms that the product's key metrics meet internationally leading standards, providing robust technical support for the global upgrade of the natural active phospholipid industry. Analysts suggest that Shineco's technological breakthrough possesses significant scarcity value and commercial potential, likely to transform the company's business structure and enhance its overall gross margin and valuation. Investors are advised to monitor closely the progress of capacity rollout, downstream customer partnerships, and international market access.
Shineco Forms Strategic Partnership with BICC
Shineco has entered into a strategic cooperation agreement with Singapore-based BICC to jointly promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase of "cross-enterprise redeemability" for cell assets on the blockchain, advancing the RWA ecosystem from "technical on-chain integration" to "real-world application. This partnership builds on Shineco's prior initiatives: establishing a Cell Digital Division, signing an agreement with Plus Me Limited for on-chain cell asset management and marketing ecosystems, and acquiring a 51% stake in Xi'an Dong'ao Health Management. The two parties will collaborate on standard-setting, compliance coordination, and scenario exploration to transition the project from "technical feasibility" to "verifiable applicability."Under the cooperation framework, Plus Me will provide full-lifecycle digital management for Shineco's compliant mesenchymal stem cells on the Ethereum mainnet, generating"digital identities" and issuing ERC-1400/ERC-20 standard "Cell Reimbursement Vouchers." Following the collaboration with BICC, BICC's iPSC stem cell storage services will be integrated into Shineco's blockchain system. Users holding" Cell Reimbursement Vouchers" will be able to redeem them in designated BICC scenarios, forming a cross-enterprise service
Shineco and Plus Me Sign Cooperation Agreement
Shineco announced the execution of a "Cellular Asset On-Chaining and Marketing Ecosystem Cooperation Agreement" with blockchain infrastructure provider Plus Me Limited. This partnership enables blockchain-based tokenization of biological cellular assets, facilitating global transfers and auditable standardized custody, creating an 'Asset On-Chaining + Application Scenarios' model in cell therapy. Under the agreement, Plus Me will deploy full lifecycle digital custody of Shineco's compliant mesenchymal stem cells on the Ethereum mainnet. Smart contracts will immutably secure asset ownership rights, issuing non-fungible digital identifiers for each cellular asset to ensure traceability and compliance. Verifiable uniqueness and regulatory compliance are cryptographically enforced through on-chain hashing. Shineco has secured a controlling 51% stake in Xi'an Dong'ao Health Management, a specialist in cryogenic cell storage and clinical applications, provides the off-chain infrastructure critical to token redemption, as of August 18.
Shineco to effect 50-for-1 reverse stock split
Shineco's Board of Directors has approved a 50:1 reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share to be effective 12:01 a.m., Eastern Time, on August 11. The Company's Common Stock will continue to trade on the Nasdaq Capital Market under the symbol "SISI" following the reverse stock split, with a new CUSIP number of 824567606. The Company expects its Common Stock to open for trading on a post-split basis on Nasdaq as of the commencement of trading on August 11. On July 3, 2025, the Company's stockholders approved a reverse stock split of the Company's Common Stock at a ratio of not less than 25:1 and note more than 60:1, with such ratio to be determined at the discretion of the Company's Board of Directors. The reverse stock split is intended to bring the Company into compliance with the minimum bid price requirement for continued listing on Nasdaq, although there is no assurance that the trading price for the Common Stock would remain over the continued listing requirements of Nasdaq in order to regain compliance with the Bid Price Requirement or sustain a continued listing of our Common Stock on the Nasdaq. Further, despite the implementation of the reverse stock split and the achievement of technical compliance with the minimum bid price requirement, there is no assurance that Nasdaq will make a positive determination to continue our listing following the review of our compliance plan by Nasdaq Listing and Hearing Review Council.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.